Abstract | CONTEXT: SETTING: Patients from two phase 3 trials (CARE MS 1 and 2, n=15) were studied in a clinical research center. PATIENTS: Five out of fifteen patients developed severe Graves' disease after a mean of 32 months following the first alemtuzumab treatment. MAIN OUTCOME MEASURES: Thyroid function tests and thyroid antibodies were assessed. In addition, endocrine tests and measurement of antibodies indicative of autoimmunity were performed. RESULTS: CONCLUSION: Since autoimmune thyroid disease is common after alemtuzumab treatment for MS, pretreatment screening and careful follow-up may allow for early diagnosis and treatment.
|
Authors | Elena Tsourdi, Matthias Gruber, Martina Rauner, Judith Blankenburg, Tjalf Ziemssen, Lorenz C Hofbauer |
Journal | Hormones (Athens, Greece)
(Hormones (Athens))
2015 Jan-Mar
Vol. 14
Issue 1
Pg. 148-53
ISSN: 2520-8721 [Electronic] Switzerland |
PMID | 25402383
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antibodies, Monoclonal, Humanized
- Antithyroid Agents
- Alemtuzumab
|
Topics |
- Adult
- Alemtuzumab
- Antibodies, Monoclonal, Humanized
(adverse effects, therapeutic use)
- Antithyroid Agents
(therapeutic use)
- Female
- Graves Disease
(chemically induced, drug therapy, surgery)
- Humans
- Male
- Middle Aged
- Multiple Sclerosis
(drug therapy)
- Thyroid Function Tests
- Thyroidectomy
|